Advanced Carbohydrate Counting and Automated Bolus Calculation
Study Details
Study Description
Brief Summary
The investigators hypothesize, that non-optimally treated carbohydrate counting-naïve patients with type 1 diabetes can achieve better metabolic control by counting carbohydrates, and that the metabolic control can be further improved with concurrent use of Accu-Chek Aviva Expert. Additionally, the investigators propose that carbohydrate counting will lead to better quality of life as a result of fewer restrictions when eating and less variation in blood glucose. Finally the investigators hypothesize that the use of Accu-Chek Aviva Expert will lead to fewer hypoglycemic episodes.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: ACC Training in advanced carbohydrate counting |
Behavioral: Advanced Carbohydrate Counting
Training in advanced carbohydrate counting.
|
Experimental: ACC + ABC Training in advanced carbohydrate counting plus the use of an automated bolus calculator. |
Device: Automated bolus calculator
Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
Other Names:
Behavioral: Advanced Carbohydrate Counting
Training in advanced carbohydrate counting.
|
Outcome Measures
Primary Outcome Measures
- Change in HbA1c [Baseline, 12 months]
Secondary Outcome Measures
- Frequency of serious hypoglycemic events [Baseline, 12 months]
Other Outcome Measures
- Frequency of glucose below, in or above target 4-8 mmol/l assessed by blinded Continuous Glucose Monitoring 6 days before study start and 6 days before ending the study [Baseline, 12 months]
- Frequency of blood glucose measurements assessed by meter download before randomization and at each visit during the study [Baseline, 12 months]
- Treatment Satisfaction [Baseline, 12 months]
Measured by Diabetes Treatment Satisfaction Questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with type 1 diabetes
-
Age >18 years
-
Diabetes duration more than 12 months
-
Multiple Daily Injections therapy (fast acting analog for meals; long acting analog as basal)
-
HbA1c between 8.0% and 11.3%
Exclusion Criteria:
-
Present or former practice of carbohydrate counting
-
Gastroparesis
-
Pregnancy or nursing
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Steno Diabetes Center | Gentofte | Denmark | 2820 |
Sponsors and Collaborators
- Steno Diabetes Center Copenhagen
- Hvidovre University Hospital
Investigators
- Principal Investigator: Eva E Hommel, MD, DMSc, Steno Diabetes Center Copenhagen
Study Documents (Full-Text)
None provided.More Information
Publications
- StenoABC